

Davide Festi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2171541/publications.pdf>

Version: 2024-02-01

171
papers

8,132
citations

53794

45
h-index

54911

84
g-index

177
all docs

177
docs citations

177
times ranked

8833
citing authors

#	ARTICLE	IF	CITATIONS
1	A population study on the prevalence of gallstone disease: The sirmione study. <i>Hepatology</i> , 1987, 7, 913-917.	7.3	503
2	Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Esophageal Varices in Patients With HCV-Related Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 646-654.	1.3	440
3	Gut microbiota and metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2014, 20, 16079.	3.3	405
4	Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 141-147.	3.7	300
5	Silybin and the liver: From basic research to clinical practice. <i>World Journal of Gastroenterology</i> , 2011, 17, 2288.	3.3	277
6	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. <i>Obesity Reviews</i> , 2004, 5, 27-42.	6.5	263
7	Gallstone recurrence after successful oral bile acid treatment. <i>Gastroenterology</i> , 1989, 97, 726-731.	1.3	190
8	Enzymatic determination of cholesterol in bile. <i>Clinica Chimica Acta</i> , 1975, 64, 337-341.	1.1	161
9	Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 392-400.	3.7	156
10	Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the Tj ETQq0 0 0,rgBT /Overlock 10 Tf	3.3	151
11	Prognostic factors for hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , 2014, 20, 5935.	3.3	143
12	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2012, 256, 706-713.	4.2	142
13	A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. <i>Journal of Hepatology</i> , 2018, 69, 308-317.	3.7	142
14	Italian consensus conference for colonic diverticulosis and diverticular disease. <i>United European Gastroenterology Journal</i> , 2014, 2, 413-442.	3.8	141
15	Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 1690.	3.3	138
16	Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. <i>Gut</i> , 2017, 66, 1252-1261.	12.1	138
17	Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: A comparative randomized study. <i>Hepatology</i> , 1982, 2, 804-810.	7.3	136
18	Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 719-724.	2.8	130

#	ARTICLE	IF	CITATIONS
19	Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. <i>Journal of Hepatology</i> , 2019, 70, 440-448.	3.7	126
20	Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: A prospective study. <i>Journal of Hepatology</i> , 2014, 60, 1158-1164.	3.7	123
21	Gallbladder motility in cholesterol gallstone disease. <i>Gastroenterology</i> , 1990, 99, 1779-1785.	1.3	122
22	Gut Microbiota and Celiac Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1461-1472.	2.3	115
23	Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. <i>Hepatology</i> , 2014, 59, 643-650.	7.3	91
24	Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 264.	3.3	91
25	Antioxidant properties of ursodeoxycholic acid. <i>Biochemical Pharmacology</i> , 2002, 64, 1661-1667.	4.4	88
26	Clinical manifestations of gallstone disease: Evidence from the multicenter Italian study on cholelithiasis (MICOL). <i>Hepatology</i> , 1999, 30, 839-846.	7.3	84
27	Bile acid malabsorption and bile acid diarrhea in intestinal resection. <i>Digestive Diseases and Sciences</i> , 1982, 27, 495-502.	2.3	82
28	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. <i>World Journal of Gastroenterology</i> , 2006, 12, 7239.	3.3	74
29	Diagnostic Effectiveness of Serum Bile Acids in Liver Diseases as Evaluated by Multivariate Statistical Methods. <i>Hepatology</i> , 2007, 3, 707-713.	7.3	73
30	Long-Term Results With Interferon Therapy in Chronic Type B Hepatitis: A Prospective Randomized Trial. <i>American Journal of Gastroenterology</i> , 1999, 94, 2246-2250.	0.4	72
31	Diet and gallstones in Italy: The cross-sectional MICOL results. <i>Hepatology</i> , 1998, 27, 1492-1498.	7.3	70
32	Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. <i>Journal of Gastroenterology</i> , 2020, 55, 927-943.	5.1	70
33	The Medical Treatment of Cholesterol Gallstones: Experience with Chenodeoxycholic Acid. <i>Digestion</i> , 1976, 14, 209-219.	2.3	69
34	Antioxidant properties of omeprazole. <i>FEBS Letters</i> , 1996, 382, 189-192.	2.8	67
35	A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 855-862.	3.7	67
36	Proton pump inhibitors in cirrhosis: Tradition or evidence based practice?. <i>World Journal of Gastroenterology</i> , 2008, 14, 2980.	3.3	64

#	ARTICLE	IF	CITATIONS
37	Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 151-157.	0.9	62
38	Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. <i>Current Therapeutic Research</i> , 1993, 54, 598-609.	1.2	60
39	A novel spleenâ€dedicated stiffness measurement by FibroScanÂ® improves the screening of highâ€risk oesophageal varices. <i>Liver International</i> , 2020, 40, 175-185.	3.9	60
40	Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. <i>Gut</i> , 2003, 52, 1030-1034.	12.1	59
41	Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. <i>Journal of Hepatology</i> , 2011, 54, 300-305.	3.7	58
42	Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2018, 50, 573-579.	0.9	56
43	Liver Stiffness Measurement Allows Early Diagnosis of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 995-1003.	2.0	56
44	Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 992-1001.	1.6	51
45	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. <i>Digestive and Liver Disease</i> , 2017, 49, 802-808.	0.9	51
46	Gut Microbiota and Its Pathophysiology in Disease Paradigms. <i>Digestive Diseases</i> , 2011, 29, 518-524.	1.9	50
47	Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases. <i>Current Clinical Pharmacology</i> , 2007, 2, 155-177.	0.6	49
48	Probiotics, Prebiotics and Other Dietary Supplements for Gut Microbiota Modulation in Celiac Disease Patients. <i>Nutrients</i> , 2020, 12, 2674.	4.1	47
49	Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-11.	1.5	46
50	A randomized controlled trial of pegylated interferon α 2a (40â€fKD) or interferon α 2a plus ribavirin and amantadine vs interferon α 2a and ribavirin in treatment-naïve patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2005, 12, 292-299.	2.0	45
51	Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy. <i>Digestion</i> , 2006, 73, 94-101.	2.3	45
52	Autoimmune liver diseases in a paediatric population with coeliac disease â€ a 10â€year single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 253-260.	3.7	42
53	Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1268-1275.e2.	4.4	42
54	Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia. <i>Hepatology</i> , 1992, 15, 1072-1078.	7.3	41

#	ARTICLE	IF	CITATIONS
55	13 C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 785-790.	3.7	41
56	Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1139-1146.	3.7	41
57	Non-invasive methods can predict oesophageal varices in patients with biliary atresia after a Kasai procedure. <i>Digestive and Liver Disease</i> , 2011, 43, 659-663.	0.9	41
58	Spleen stiffness measurement for assessing the response to β -blockers therapy for high-risk esophageal varices patients. <i>Hepatology International</i> , 2020, 14, 850-857.	4.2	41
59	Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1993, 38, 896-902.	2.3	40
60	Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients. <i>Digestive Diseases and Sciences</i> , 1979, 24, 123-128.	2.3	39
61	Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. <i>World Journal of Gastroenterology</i> , 2004, 10, 3099.	3.3	38
62	Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: Gamma GT levels predictive for response. <i>Digestive Diseases and Sciences</i> , 1994, 39, 866-870.	2.3	37
63	Dissolution of gallbladder stones with methyl tert-butyl ether and stone recurrence: a European survey. <i>Digestive Diseases and Sciences</i> , 1998, 43, 911-920.	2.3	37
64	The Loiano-Monghidoro population-based study of <i>Helicobacter pylori</i> infection: prevalence by ¹³ C-urea breath test and associated factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1001-1007.	3.7	37
65	Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 446-454.	2.8	37
66	Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 463-484.	3.0	34
67	<i>Helicobacter Pylori</i> Infection Causes Persistent Platelet Activation In Vivo Through Enhanced Lipid Peroxidation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 246-251.	2.4	33
68	Natural History of Small Gallbladder Polyps Is Benign: Evidence From a Clinical and Pathogenetic Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 624-629.	0.4	32
69	Micronucleus frequency in human peripheral blood lymphocytes as a biomarker for the early detection of colorectal cancer risk. <i>Mutagenesis</i> , 2014, 29, 221-225.	2.6	31
70	Cephalosporins are scavengers of hypochlorous acid. <i>Biochemical Pharmacology</i> , 1995, 49, 1249-1254.	4.4	30
71	Transjugular intrahepatic portosystemic shunt: A case report of rescue management of unrestrainable variceal bleeding in a pregnant woman. <i>Digestive and Liver Disease</i> , 2008, 40, 387-390.	0.9	29
72	Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. <i>Liver International</i> , 2016, 36, 1313-1321.	3.9	29

#	ARTICLE	IF	CITATIONS
73	Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. <i>World Journal of Gastroenterology</i> , 2003, 9, 1487.	3.3	29
74	The estimation of phospholipids in bile. <i>Clinica Chimica Acta</i> , 1976, 68, 159-166.	1.1	28
75	Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. <i>Gastroenterology</i> , 1991, 101, 490-496.	1.3	28
76	Non-invasive tests for the prediction of primary hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 3326-3343.	3.3	28
77	A Novel FibroScan Examination Dedicated to Spleen Stiffness Measurement. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1616-1626.	1.5	27
78	Sluggish Small Bowel Motility Is Involved in Determining Increased Biliary Deoxycholic Acid in Cholesterol Gallstone Patients. <i>American Journal of Gastroenterology</i> , 1999, 94, 2453-2459.	0.4	25
79	Is It Possible to Predict the Clinical Course of Gallstone Disease? Usefulness of Gallbladder Motility Evaluation in a Clinical Setting. <i>American Journal of Gastroenterology</i> , 2006, 101, 2576-2581.	0.4	25
80	Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon. <i>Digestive Diseases and Sciences</i> , 2016, 61, 673-683.	2.3	25
81	Clinical application of faecal calprotectin in ulcerative colitis patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1418-1424.	1.6	24
82	Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. <i>World Journal of Hepatology</i> , 2018, 10, 731-742.	2.0	24
83	Symptoms discriminate irritable bowel syndrome from organic gastrointestinal diseases and food allergy. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 981-988.	1.6	23
84	Plasma antioxidant enzymes and clastogenic factors as possible biomarkers of colorectal cancer risk. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 714, 88-92.	1.0	23
85	Use of hormone replacement therapy in Italian women aged 50-70 years. <i>Maturitas</i> , 2004, 49, 241-251.	2.4	22
86	Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-6.	1.9	22
87	Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2022, 54, 103-110.	0.9	22
88	Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28486-28497.	4.1	21
89	How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests. <i>Liver International</i> , 2019, 39, 49-53.	3.9	21
90	Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial. <i>World Journal of Gastroenterology</i> , 2003, 9, 1491.	3.3	21

#	ARTICLE	IF	CITATIONS
91	Focal nodular hyperplasia of the liver after intensive treatment for pediatric cancer: is hematopoietic stem cell transplantation a risk factor?. <i>European Journal of Pediatrics</i> , 2011, 170, 807-812.	2.7	20
92	Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Rectal Anastomosis for Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1016-1024.	2.3	19
93	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 777-787.e17.	4.4	19
94	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 121-136.	2.4	18
95	Relationship between hepatic haemodynamics assessed by Doppler ultrasound and liver stiffness. <i>Digestive and Liver Disease</i> , 2012, 44, 154-159.	0.9	18
96	Efficacy of ursodeoxycholic acid in association with α -interferon for chronic hepatitis C in α -interferon non-responder patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 511-516.	1.6	17
97	Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2002, 34, 523-527.	0.9	17
98	Focal nodular hyperplasia of the liver in children after hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2013, 17, 479-486.	1.0	16
99	Benign Hepatic Nodular Lesions After Treatment for Childhood Cancer. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, 151-155.	1.8	16
100	Prognostic Value of the Albumin-Bilirubin Grade for the Prediction of Post-Hepatectomy Liver Failure: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2011.	2.4	16
101	Prevalence of gallstone disease in first-degree relatives of patients with cholelithiasis. <i>World Journal of Gastroenterology</i> , 2005, 11, 6508.	3.3	16
102	Inter and intra-observer variation in ultrasonographic detection of gallstones: The Multicenter Italian Study on Epidemiology of Cholelithiasis (M.I.COL.). <i>European Journal of Epidemiology</i> , 1989, 5, 51-57.	5.7	15
103	Clinical significance of chronic hyperamylasemia. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1517-1522.	2.3	15
104	Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients. <i>Ultraschall in Der Medizin</i> , 2020, , .	1.5	15
105	Clinical impact of sarcopenia assessment in patients with liver cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 377-388.	3.0	15
106	Nerve fiber overgrowth in patients with symptomatic diverticular disease. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13575.	3.0	14
107	Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis. <i>Cancers</i> , 2022, 14, 1935.	3.7	14
108	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1039-1053.	3.0	13

#	ARTICLE	IF	CITATIONS
109	Longitudinal evaluation of liver stiffness in three pediatric patients with venoocclusive disease. <i>Pediatric Transplantation</i> , 2019, 23, e13456.	1.0	13
110	Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. <i>European Journal of Radiology</i> , 2022, 147, 110010.	2.6	13
111	“Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?”. <i>Digestive and Liver Disease</i> , 2019, 51, 456-457.	0.9	12
112	Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness. <i>JHEP Reports</i> , 2021, 3, 100289.	4.9	12
113	Alterations of exocrine pancreas in end-stage renal disease do they reflect a clinically relevant uremic pancreopathy?. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2576-2581.	2.3	11
114	¹³ C-Urea Breath Test for <i>Helicobacter pylori</i> Infection: Stability of Samples over Time. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 942-943.	1.5	11
115	Co-dispensing of contraindicated medications in patients using cisapride in Italy. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 469-476.	1.9	11
116	Dysbiosis in Celiac Disease Patients With Persistent Symptoms on Gluten-Free Diet: A Condition Similar to that Present in Irritable Bowel Syndrome Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 598.	0.4	11
117	Adverse Food Reaction and Functional Gastrointestinal Disorders: Role of the Dietetic Approach. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 319-327.	0.9	11
118	Prediction of posthepatectomy liver failure: Role of SSM and LSPS. <i>Journal of Surgical Oncology</i> , 2019, 119, 400-401.	1.7	10
119	Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 449-456.	0.9	10
120	Non-invasive panel tests for gastrointestinal motility monitoring within the MARS-500 Project. <i>World Journal of Gastroenterology</i> , 2013, 19, 2208.	3.3	10
121	Transmural distribution of antioxidant defences and lipid peroxidation in the rabbit left ventricular myocardium. <i>Pflugers Archiv European Journal of Physiology</i> , 1994, 427, 432-436.	2.8	8
122	Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2478-2483.	2.3	8
123	Risk Factors for Gallstone Formation During Weight Loss. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 613.	4.4	8
124	Primary biliary cholangitis “primary sclerosing cholangitis in an evolving overlap syndrome: A case report. <i>Gastroenterology & Hepatology</i> , 2017, 40, 669-671.	0.5	8
125	Imaging Software-Based Sarcopenia Assessment in Gastroenterology: Evolution and Clinical Meaning. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	1.9	8
126	Effect of Gemfibrozil Administration on Biliary Lipid Secretion in Hyperlipidemic Patients. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 1227-1234.	1.5	7

#	ARTICLE	IF	CITATIONS
127	A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 129-136.	3.7	7
128	Coeliac disease and autoimmune hepatitis: Gluten-free diet can influence liver disease outcome. <i>Digestive and Liver Disease</i> , 2011, 43, 247.	0.9	7
129	MRI Patterns in a Case of 6-Thioguanine-Related Hepatic Sinusoidal Obstruction Syndrome. <i>American Journal of Gastroenterology</i> , 2016, 111, 767.	0.4	7
130	Spleen Stiffness by Ultrasound Elastography. , 2018, , 113-137.		7
131	Ablation for hepatocellular carcinoma: beyond the standard indications. <i>Medical Oncology</i> , 2020, 37, 23.	2.5	7
132	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.9	7
133	Natural History of Small Gallbladder Polyps Is Benign. <i>American Journal of Gastroenterology</i> , 2009, 104, 624-629.	0.4	7
134	Evaluation of the Ileal Absorption Capacity for Bile Acids in the Rabbit. <i>European Surgical Research</i> , 1990, 22, 93-100.	1.3	6
135	Development and application of a simple and powerful tool for nutrition and lifestyle education for the Italian general population by general practitioners and family paediatricians. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009, 2, 139-144.	0.5	6
136	Letter: FibroTest for staging fibrosis in non-â€œalcoholic fatty liver disease â€œ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 656-657.	3.7	6
137	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	3.7	6
138	Update on <i>Helicobacter pylori</i> research. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 613-614.	1.6	5
139	The UDCA dosage deficit: a fate shared with CDCA. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 213-216.	1.6	5
140	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. <i>Digestive and Liver Disease</i> , 2021, 53, 202-209.	0.9	5
141	Hepatic uptake and biliary secretion of bile acids in the perfused rat liver. <i>Pharmacological Research</i> , 1992, 25, 51-61.	7.1	4
142	Enlarged pancreas: not always a cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 107-108.	1.3	4
143	Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?. <i>Pancreas</i> , 2020, 49, 1342-1347.	1.1	4
144	The role of liver and spleen elastography in advanced chronic liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 151-163.	0.5	4

#	ARTICLE	IF	CITATIONS
145	Mesalazine and Rifaximin in Symptomatic Uncomplicated Diverticular Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 532-532.	0.4	3
146	Noninvasive Parameters for Predicting Esophageal Varices in Children: Their Sequential Use Provides the Best Accuracy. <i>Gastroenterology</i> , 2012, 142, e32.	1.3	3
147	Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome. <i>Ultraschall in Der Medizin</i> , 2017, 38, 515-522.	1.5	3
148	Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 505-507.	1.5	3
149	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2022, 11, 618-629.	2.8	3
150	Erythromycin and gallbladder motor function. <i>Gastroenterology</i> , 1993, 105, 1589.	1.3	2
151	Development and application of a simple and powerful tool for nutrition and lifestyle education for the Italian general population by general practitioners and family paediatricians. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009, 2, 139-144.	0.5	2
152	Are Noninvasive Methods Clinically Useful in Advanced, Decompensated Liver Cirrhosis When "Les Jeux Sont Faits"? <i>Radiology</i> , 2016, 278, 304-306.	7.3	2
153	Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors. <i>Digestive and Liver Disease</i> , 2017, 49, 1128-1132.	0.9	2
154	Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection". <i>Journal of Hepatology</i> , 2019, 70, 809-810.	3.7	2
155	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101925.	1.5	2
156	Gallstone epidemiology. <i>Current Opinion in Gastroenterology</i> , 1994, 10, 552-557.	2.3	1
157	Bacterial flora, gas and antibiotics. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 54-57.	0.2	1
158	A new point-of-care portable immunosensor for non-invasive assessment of oro-ileal transit time by oral fluid tauroursodeoxycholate measurement after its oral load. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 81-82, 1-7.	2.8	1
159	Telbivudine treatment for fulminant HBV hepatitis. <i>Journal of Digestive Diseases</i> , 2013, 14, n/a-n/a.	1.5	1
160	Reply to Letter. <i>Annals of Surgery</i> , 2015, 261, e105-e106.	4.2	1
161	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. <i>Journal of Hepatology</i> , 2020, 73, S751-S752.	3.7	1
162	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1343-1343.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Biliary symptoms, gallbladder motility, and cholecystectomy. <i>Hepatology</i> , 2007, 45, 259-260.	7.3	0
164	Percutaneous liver biopsy in the clinical management of hepatocellular carcinoma: Back to the future. <i>Hepatology</i> , 2011, 53, 2147-2147.	7.3	0
165	FRI-290-The role of bile acids profile and insulin reistance for the prediction of gallstone disease in a prospective cohort of blood donors. <i>Journal of Hepatology</i> , 2019, 70, e523.	3.7	0
166	A novel nomogram based on liver stiffness to predict the comprehensive complication index after liver resection in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S259-S260.	3.7	0
167	The Assessment of Portal Hypertension. , 2021, , 159-171.		0
168	Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study. <i>Blood</i> , 2018, 132, 2098-2098.	1.4	0
169	Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. , 2008, , 215-236.		0
170	Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years. <i>Nutrients</i> , 2021, 13, 4131.	4.1	0
171	Effect of chenodiol on the small intestine. Unimpaired structure and function during therapy for gallstone dissolution. <i>JAMA - Journal of the American Medical Association</i> , 1981, 246, 2597-2601.	7.4	0